Advertisement


Anita Mahajan, MD, on Radiotherapy Advances in the CNS and Aerodigestive Tract

2015 ASTRO Annual Meeting

Advertisement

Anita Mahajan, MD, of MD Anderson Cancer Center, summarizes results from three clinical trials on radiation therapy for ependymoma, locally advanced thoracic esophageal squamous cell carcinoma, and meningioma (Abstracts 31, 1, 7).



Related Videos

Breast Cancer

Reshma Jagsi, MD, DPhil, on the Initial Results of the TBCRC 024 Study on Breast Cancer

Reshma Jagsi, MD, DPhil, of the University of Michigan Health System, discusses this multicenter phase 1 study of veliparib given concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer (Abstract 312).

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Results of NRG Oncology/RTOG 9601

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).

Skin Cancer
Head and Neck Cancer
Breast Cancer

Catherine C. Park, MD, on Novel Clinical Paradigms

Catherine C. Park, MD, of the University of California, San Francisco, summarizes results from three clinical trials of radiation therapy for various cancers: metastatic melanoma, oropharyngeal squamous cell carcinoma, and breast cancer (Abstracts 215, 3, and LBA7).

Lung Cancer

Roy Decker, MD, PhD, on Chemoradiation in Elderly Patients With Limited-Stage SCLC

Roy Decker, MD, PhD, of Yale University School of Medicine, discusses a National Cancer Database analysis that showed elderly patients with limited-stage small cell lung cancer can benefit from adding concurrent radiation to chemotherapy (Abstract 1010).

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Results From RTOG 0415

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses this phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).

Advertisement

Advertisement




Advertisement